文献速递慢性肾脏病

DAPA-CKD试验的 extrapolated 长期效应:一项模型分析

Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis.
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

本研究基于DAPA-CKD试验数据构建马尔可夫模型,模拟达格列净与安慰剂在慢性肾脏病(CKD)伴白蛋白尿患者中10年内的长期临床结局。结果显示,达格列净使患者处于CKD 1-3期的时间更长、4-5期的时间更短,每1000例患者中预计可避免83例死亡和51例启动肾脏替代治疗,并减少因心力衰竭住院和肾功能骤降事件。

要点

  • 基于DAPA-CKD试验的模型预测,达格列净在10年内每1000例患者可避免83例死亡和51例启动肾脏替代治疗。
  • 达格列净组患者处于CKD 1-3期的时间较安慰剂组延长0.65年(95% CrI 0.41, 0.90),处于4-5期的时间缩短0.23年(95% CrI -0.45, 0.00)。
  • 预测达格列净可减少每1000例患者中19例因心力衰竭住院和39例肾功能骤降事件。

核心结论

  • 在CKD的标准治疗基础上加用达格列净,预计可带来超越DAPA-CKD试验所证明的长期心肾获益,患者预计寿命更长且并发症更少。

研究设计与样本

  • 本研究为基于DAPA-CKD试验数据的建模分析,使用马尔可夫模型外推达格列净或安慰剂治疗患者10年时间范围内的每1000例患者事件发生率和CKD进展率。

主要发现

  • 外推10年期间,随机分配至达格列净的患者较安慰剂组处于CKD 1-3期的时间更长,处于4-5期的时间更短,每患者分别为0.65年(95% CrI 0.41, 0.90)和-0.23年(95% CrI -0.45, 0.00)。
  • 达格列净预计每1000例患者中可避免83例死亡和51例启动肾脏替代治疗。
  • 预测达格列净组因心力衰竭住院和肾功能骤降的发生率降低,每1000例患者分别预计减少19和39例事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial assessed dapagliflozin versus placebo, in addition to standard therapy, in patients with chronic kidney disease (CKD) and albuminuria, and was terminated prematurely due to overwhelming efficacy. The study objective was to model the long-term clinical outcomes of DAPA-CKD beyond the trial follow-up. METHODS: A Markov model extrapolated event incidence per 1000 patients and CKD progression rates for patients receiving dapagliflozin or placebo over a 10-year time horizon. We derived treatment-specific CKD stage transition matrices using DAPA-CKD trial data. We extrapolated relevant efficacy endpoints using parametric survival equations for all-cause mortality and generalized estimating equations for recurrent events. RESULTS: When extrapolated over a 10-year period, patients randomized to dapagliflozin spent more time in CKD stages 1-3 and less in stages 4-5 than placebo [0.65 (95% CrI 0.41, 0.90) and -0.23 (95% CrI -0.45, 0.00) years per patient, respectively]. Dapagliflozin prevented an estimated 83 deaths and 51 patients initiating kidney replacement therapy per 1000 patients over 10 years. Predicted rates of hospitalized heart failure and abrupt declines in kidney function were reduced (19 and 39 estimated events per 1000 patients, respectively). CONCLUSIONS: Adding dapagliflozin to standard therapeutic management of CKD is expected to have long-term cardiorenal benefit beyond what has been demonstrated in the DAPA-CKD trial, with patients predicted to live longer with fewer complications.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. McEwan P, Boyce R, Sanchez JJG, et al. Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis. Nephrol Dial Transplant. 2023. PMID: 36301617. doi:10.1093/ndt/gfac280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。